Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06788769
Recruiting Observational

Study of Clostridioides Difficile in Infants

NCT06788769 · tracked via the Priya Life Science China tracker
Sponsor
Westlake University
Phase
Observational
Started
2024-07-01
Last updated
2025-01-23

Condition(s) studied

Clostridioides Difficile Infection

Study summary

Clostridioides difficile infection (CDI) poses an increasing threat to infant and young child health, with detection rates rising annually. This retrospective study aims to explore the epidemiological characteristics, clinical manifestations, and potential biomarkers of CDI in children aged 0-2 years by examining three cohorts: (1) infants diagnosed with CDI, (2) asymptomatic carriers of C. difficile, and (3) healthy controls. Fecal samples from each group will undergo metagenomic sequencing and metabolomic profiling, coupled with questionnaire-based surveys for risk factor assessment. The findings are anticipated to identify key high-risk factors, elucidate the pathogenic mechanisms underlying infant CDI, and support the development of early diagnostic tools and preventive strategies.

Eligibility

Sex
ALL
Min age
1 Day
Max age
2 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age Range: Infants aged 0 to 2 years (inclusive) at the time of sample collection or medical record documentation. 2. Data Availability: Complete medical records or available stool samples within the study's retrospective time frame. 3. Group-Specific Criteria: CDI Patients: Documented diarrhea or related gastrointestinal symptoms, with laboratory-confirmed C. difficile by PCR or culture. Asymptomatic Carriers: Positive C. difficile test (PCR or culture) in the absence of diarrhea or other clinical CDI symptoms. Healthy Controls: Negative C. difficile test and no gastrointestinal symptoms indicative of CDI. 4. Consent/Authorization:Retrospective data (e.g., existing medical records or stored biosamples) may be included under a waiver of consent if approved by the institutional review board (IRB). However, any new information obtained directly from participants or their guardians (e.g., via questionnaires) requires explicit informed consent. Exclusion Criteria: 1. Incomplete Data: Infants whose medical records lack sufficient information to confirm their CDI status or those without adequate stool sample results. 2. Ambiguous Diagnosis: Patients presenting with other infectious diseases or conditions that could not rule out alternative diagnoses for diarrhea (e.g., confirmed concurrent viral or parasitic infections) without conclusive C. difficile testing. 3. Severe Comorbidities: Infants with life-threatening congenital conditions (e.g., severe immunodeficiency syndromes) if these conditions significantly alter the gut microbiota or confound CDI diagnosis.

Primary outcome measure(s)

  • Prevalence of Clostridioides difficile infection (CDI) and asymptomatic carriage in infants — Data from medical records and stool sample tests collected retrospectively between July 2024 and December 2026.
    The prevalence of CDI and asymptomatic C. difficile carriage will be determined by testing fecal samples for C. difficile using PCR and/or culture methods. Participants are categorized into three groups based on clinical symptoms (diarrhea, abdominal pain, or fever) and laboratory confirmation (positive PCR or stool culture). Specifically, the primary outcome assesses: 1. The proportion of infants (0-2 years) testing positive for C. difficile who exhibit clinical symptoms (CDI patients). 2. The proportion of infants (0-2 years) testing positive but showing no symptoms (asymptomatic carriers), and the proportion of infants testing negative (healthy controls).

Trial sites (1)

FacilityCityRegionStatus
Hangzhou First People's Hospital Hangzhou Zhejiang Recruiting

More Westlake University trials in China

Dynamic Monitoring of Urinary Electrolytes Active, not recruiting
Wenzhou Gestational Diabetes Cohort Active, not recruiting
Westlake Frequent-sampling Cohort 2 Active, not recruiting
Westlake Aging Cohort (WeAC) Recruiting
A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients Recruiting

Other trials for the same condition

Washed Microbiota Transplantation for Clostridioides Difficile Infection Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection Recruiting
Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections Recruiting
CMTS0929 for Clostridioides Difficile Infection Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06788769 on ClinicalTrials.gov ↗ ← All trials in China